fbpx > Skip to main content

Vivos Therapeutics Announces Integrative Cardiologist Dr. Mimi Guarneri as New Medical Director of Clinical Education

HIGHLANDS RANCH
Colorado, April 14, 2021

Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (OSA), today announced the appointment of Mimi Guarneri, MD, FACC as an independent consultant serving in the role of Medical Director of Clinical Education, effective April 1, 2021.

Dr. Mimi Guarneri is widely acclaimed as a leading Integrative Cardiologist in America. She is Board-certified in Cardiovascular Disease, Internal Medicine, Nuclear Cardiology, and Integrative Holistic Medicine. Dr. Guarneri is a Founder and President of The Academy of Integrative Health and Medicine. She serves on the Founding Board of the American Board Physician Specialties in Integrative Medicine and is a Clinical Associate Professor at the University of California, San Diego. An award-winning physician and researcher, she has been recognized for her national leadership in Integrative Medicine by the Bravewell Collaborative, and she served as chair of the Bravewell Clinical Network for Integrative Medicine. Dr. Guarneri was honored as the ARCS Scientist of the Year in 2009. A highly sought speaker, Dr. Guarneri presents both nationally and internationally and in 2017 presented at the Vatican on Health and the Climate. Dr. Guarneri has been interviewed on many nationally syndicated television shows including The Dr. Oz Show, NBC Today, and PBS Full Focus and To the Contrary.

Among her other private practice endeavors, Dr. Guarneri owns and operates the Company’s first Pneusomnia Center for Craniofacial Sleep Medicine located in Del Mar, California, and her duties for the Company will include the promotion and expansion of the Company’s Medical Integration Division.

“We are very excited to welcome Dr. Guarneri to Vivos Therapeutics in this new capacity,” said Kirk Huntsman, Vivos’ Chairman and Chief Executive Officer. “As a global medical leader in comprehensive and holistic approaches to cardiovascular disease and sleep disorders, she will be a valuable addition to our growing organization. Her wealth of experience and credibility as an award-winning physician and researcher will help inform other physicians about our breakthrough diagnostic and treatment technologies.”

Dr. Guarneri commented, “I am excited to be a part of such a dynamic organization so passionately focused on finding and treating patients with obstructive sleep apnea. As a practicing cardiologist, I see the ravages of OSA in my patients every day, and I find the Vivos System to be a novel approach that advances our ability to give patients the relief they need.”

About Vivos Therapeutics, Inc.

Vivos Therapeutics Inc. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep disordered breathing, including obstructive sleep apnea (OSA).  Vivos believes that its Vivos System technology represents the first clinically effective non-surgical, non-invasive, non-pharmaceutical and cost-effective solution for people with mild-to-moderate OSA. Combining technologies and protocols that alter the size, shape and position of the tissues of the upper human airway, the Vivos System opens airway space and can eliminate or significantly reduce symptoms and conditions associated with mild-to-moderate OSA.  The Vivos System has been shown to significantly lower Apnea Hypopnea Index scores and improve other conditions associated with OSA.  Sales of the Vivos System are driven by the Vivos Integrated Practice (VIP) program, which offers dentists training and value-added services in connection with their use of the Vivos System.

Cautionary Note Regarding Forward-Looking Statements 

This press release and statements of the Company’s management made in connection therewith contain “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events, particularly with respect to the public offering described herein. Words such as “may”, “should”, “expects”, “intends”, “plans”, “believes”, “anticipates”, “hopes”, “estimates” and variations of such words and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond Vivos’ control. Actual results (including the anticipated benefits of Dr. Guarneri’s association with the Company as described herein) may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the risk factors described in Vivos’ filings with the Securities and Exchange Commission (“SEC”). Vivos’ filings can be obtained free of charge on the SEC’s website at www.sec.gov. Except to the extent required by law, Vivos expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Vivos’ expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Investor Relations Contact:

Edward Loew
Investor Relations Officer
(602) 903-0095
[email protected]

Media Relations Contact:

Caitlin Kasunich / Jenny Robles
KCSA Strategic Communications
(212) 896-1241 / (917) 420-1444
[email protected] / [email protected]